Compound Detail
CHEMBL182
GANCICLOVIR 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL182 |
| Name | GANCICLOVIR |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | IRSCQMHQWWYFCW-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
| Active Moiety | CHEMBL1159869 |
30
Targets
556
Activities
3
Assay Types
29
PK Parameters
20
Publications
14
Known Names
20
Indications
1
Mechanisms
Molecular Properties
255.2
MW (Da)
-1.97
ALogP
8
HBA
4
HBD
139.3
PSA (Ų)
0.49
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1989 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Human herpesvirus 1 DNA polymerase inhibitor | INHIBITOR | DNA polymerase catalytic subunit | ✓ | ✓ |
Indications
Cytomegalovirus Retinitis Eye Infections HIV Infections Virus Diseases Conjunctivitis Cytomegalovirus Infections Infections Carcinoma, Hepatocellular Diabetes Mellitus, Type 1 Fallopian Tube Neoplasms Glioblastoma Graft vs Host Disease Lymphoma Ovarian Neoplasms Peritoneal Neoplasms Central Nervous System Neoplasms Kidney Diseases Melanoma Mesothelioma Neuroblastoma
ATC Classification
J05AB06
ganciclovir
Level 1: ANTIINFECTIVES FOR SYSTEMIC USE
Level 2: ANTIVIRALS FOR SYSTEMIC USE
S01AD09
ganciclovir
Level 1: SENSORY ORGANS
Level 2: OPHTHALMOLOGICALS
Drug Warnings
Black Box Warning
carcinogenicity
Black Box Warning
hematological toxicity
Black Box Warning
teratogenicity
Activity Summary
EC50 379 meas. best 8.92
IC50 176 meas. best 8.72
Kd 1 meas. best 4.8
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| E6SM CHEMBL614149 | EC50 | 8.92 | 8.92 | 1.2 | 2 |
| ADMET CHEMBL612558 | IC50 | 8.72 | 6.6115 | 1.9 | 13 |
| Cytomegalovirus CHEMBL613134 | EC50 | 8.59 | 5.6505 | 2.6 | 20 |
| Human alphaherpesvirus 2 CHEMBL370 | EC50 | 8.0 | 7.1459 | 10.0 | 37 |
| Human alphaherpesvirus 1 CHEMBL377 | EC50 | 8.0 | 6.6697 | 10.0 | 66 |
| Human betaherpesvirus 5 CHEMBL371 | EC50 | 7.4 | 5.5259 | 40.0 | 176 |
| Human gammaherpesvirus 4 CHEMBL613124 | IC50 | 7.3 | 7.3 | 50.0 | 1 |
| HEL CHEMBL613888 | EC50 | 7.22 | 5.8318 | 60.0 | 11 |
| Human alphaherpesvirus 2 CHEMBL370 | IC50 | 7.0 | 5.75 | 100.0 | 2 |
| Human alphaherpesvirus 1 CHEMBL377 | IC50 | 7.0 | 5.5493 | 100.0 | 28 |
| Human betaherpesvirus 5 CHEMBL371 | IC50 | 6.85 | 5.3633 | 140.0 | 73 |
| HEL CHEMBL613888 | IC50 | 6.3 | 5.69 | 500.0 | 4 |
| Homo sapiens CHEMBL372 | EC50 | 6.3 | 6.3 | 500.0 | 1 |
| Cytomegalovirus CHEMBL613134 | IC50 | 6.23 | 5.64 | 590.0 | 5 |
| Human alphaherpesvirus 3 CHEMBL613132 | EC50 | 6.23 | 5.678 | 590.0 | 5 |
| HFF CHEMBL614071 | IC50 | 6.22 | 5.5045 | 600.0 | 20 |
| Unchecked CHEMBL612545 | EC50 | 6.05 | 5.8367 | 900.0 | 6 |
| Felid alphaherpesvirus 1 CHEMBL612743 | EC50 | 6.05 | 5.555 | 900.0 | 10 |
| Unchecked CHEMBL612545 | IC50 | 5.89 | 5.89 | 1300.0 | 1 |
| Transitional endoplasmic reticulum ATPase CHEMBL1075145 | IC50 | 5.89 | 5.89 | 1300.0 | 1 |
| MRC5 CHEMBL614181 | IC50 | 5.85 | 5.6229 | 1400.0 | 7 |
| NON-PROTEIN TARGET CHEMBL3879801 | EC50 | 5.68 | 5.5333 | 2100.0 | 3 |
| Human alphaherpesvirus 3 CHEMBL613132 | IC50 | 5.55 | 5.55 | 2800.0 | 1 |
| MEF CHEMBL614342 | IC50 | 5.47 | 5.47 | 3400.0 | 1 |
| KB CHEMBL398 | IC50 | 5.46 | 5.46 | 3500.0 | 1 |
| Hepatitis B virus CHEMBL613497 | EC50 | 5.4 | 5.4 | 4000.0 | 1 |
| Human gammaherpesvirus 4 CHEMBL613124 | EC50 | 5.3 | 5.096 | 5000.0 | 5 |
| MEF CHEMBL614342 | EC50 | 5.3 | 5.3 | 5000.0 | 1 |
| Human immunodeficiency virus 1 CHEMBL378 | EC50 | 5.3 | 5.3 | 5000.0 | 1 |
| Murid betaherpesvirus 1 CHEMBL613495 | EC50 | 5.26 | 5.26 | 5500.0 | 1 |
| MRC5 CHEMBL614181 | EC50 | 5.03 | 5.03 | 9400.0 | 1 |
| Human herpesvirus 5 strain AD169 CHEMBL613123 | EC50 | 4.92 | 4.92 | 12000.0 | 1 |
| Macacine alphaherpesvirus 1 CHEMBL3301403 | EC50 | 4.84 | 4.7122 | 14500.0 | 27 |
| Purine nucleoside phosphorylase CHEMBL1169594 | Kd | 4.8 | 4.8 | 15848.9 | 1 |
| CFU-GM CHEMBL614779 | IC50 | 4.72 | 4.72 | 19000.0 | 1 |
| Caviid betaherpesvirus 2 CHEMBL614682 | EC50 | 4.59 | 4.59 | 25900.0 | 1 |
| Osteoclast-like CHEMBL614359 | IC50 | 4.52 | 4.52 | 30000.0 | 1 |
| Human adenovirus 2 CHEMBL613715 | IC50 | 4.46 | 4.46 | 35000.0 | 1 |
| Human gammaherpesvirus 8 CHEMBL612780 | IC50 | 4.16 | 4.125 | 70000.0 | 2 |
| Vaccinia virus CHEMBL613493 | EC50 | 4.0 | 4.0 | 100000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 209.7 | - | Rattus norvegicus |
| AUC | 182.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 170.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 82.5 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 78.4 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1720.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1700.0 | ng.hr.mL-1 | Rattus norvegicus |
| CL | 4.6 | mL.min-1.kg-1 | Homo sapiens |
| CL | 4.6 | mL.min-1.kg-1 | Homo sapiens |
| CL | 0.5 | mL.min-1.kg-1 | Homo sapiens |
| CL | 4.6 | mL.min-1.kg-1 | Homo sapiens |
| CL | 7.49 | L/hr | Homo sapiens |
| CL | 10.2 | L/hr | Homo sapiens |
| CL | 9.65 | L/hr | Homo sapiens |
| CL | 6.34 | L/hr | Homo sapiens |
| F | 3.6 | % | Rattus norvegicus |
| F | 7.3 | % | Homo sapiens |
| F | 0.825 | % | Homo sapiens |
| F | 0.76 | % | Homo sapiens |
| Fu | 0.99 | - | Homo sapiens |
| Fu | 0.99 | - | Homo sapiens |
| Ka | 0.895 | /hr | Homo sapiens |
| Ka | 0.971 | /hr | Homo sapiens |
| MRT | 3.7 | hr | Homo sapiens |
| T1/2 | 3.7 | hr | Homo sapiens |
| Vd | 31.9 | l | Homo sapiens |
| Vd | 32.0 | l | Homo sapiens |
| Vd | 31.1 | l | Homo sapiens |
| Vd | 32.0 | l | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine